- Home
- EPIX vs GOSS Comparison
EPIX vs GOSS Comparison
Compare EPIX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- GOSS
- Stock Information
- Founded
- EPIX 2009
- GOSS 2015
- Country
- EPIX Canada
- GOSS United States
- Employees
- EPIX N/A
- GOSS N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- GOSS Health Care
- Exchange
- EPIX Nasdaq
- GOSS Nasdaq
- Market Cap
- EPIX 209.4M
- GOSS 212.9M
- IPO Year
- EPIX N/A
- GOSS 2019
- Fundamental
- Price
- EPIX $1.72
- GOSS $0.74
- Analyst Decision
- EPIX Hold
- GOSS Strong Buy
- Analyst Count
- EPIX 4
- GOSS 5
- Target Price
- EPIX $9.50
- GOSS $9.20
- AVG Volume (30 Days)
- EPIX 2.4M
- GOSS 881.6K
- Earning Date
- EPIX 12-10-2024
- GOSS 11-07-2024
- Dividend Yield
- EPIX N/A
- GOSS N/A
- EPS Growth
- EPIX N/A
- GOSS N/A
- EPS
- EPIX N/A
- GOSS N/A
- Revenue
- EPIX N/A
- GOSS $105,322,000.00
- Revenue This Year
- EPIX N/A
- GOSS N/A
- Revenue Next Year
- EPIX N/A
- GOSS N/A
- P/E Ratio
- EPIX N/A
- GOSS N/A
- Revenue Growth
- EPIX N/A
- GOSS N/A
- 52 Week Low
- EPIX $1.40
- GOSS $0.50
- 52 Week High
- EPIX $11.67
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- EPIX 23.15
- GOSS 22.63
- Support Level
- EPIX $1.75
- GOSS $0.78
- Resistance Level
- EPIX $1.89
- GOSS $0.92
- Average True Range (ATR)
- EPIX 0.19
- GOSS 0.05
- MACD
- EPIX -0.10
- GOSS -0.01
- Stochastic Oscillator
- EPIX 7.36
- GOSS 0.00
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.